In plain English
Merck & Co Inc. develops and sells prescription medicines and vaccines, focusing on oncology, immunology, and infectious diseases. The…
Company stock · NYSE · USD
MRK
Merck & Co Inc
$145.27
Today
−$1.97-1.34%
vs yesterday’s close
Live price
- Opened at
- $145.02
- Day high
- $145.44
- Day low
- $143.41
- Yesterday’s close
- $147.24
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Size
- Large company
- Market value
- $358.4 billion
- Number of shares
- 2.47 billion
- Country
- US
- Went public
- Jan 1, 1941
- Exchange
- NYSE
- Website
- merck.com
Themes
Price chart Pro
Loading chart…
Loading chart…
Company briefing
What MRK is
Plain English context — why the name shows up in the news, and what to watch next.
Latest on this name
Insights & deeper context
24 recent cards — open any for the full deeper dive.
Merck And Moderna Report Phase 3 Melanoma Trial Results For Personalized mRNA Cancer Therapy; Intismeran Plus KEYTRUDA Cuts Melanoma Recurrence Or Death Risk By 42%
In brief
Intismeran plus KEYTRUDA cuts melanoma recurrence or death risk by up to 58%, marking a major advance for personalized mRNA cancer therapy.
Why Is Moderna Stock Sinking Thursday?
In brief
Moderna’s shares plunged after a leaked Phase 3 result suggested a smaller benefit than earlier studies, sparking doubts about the vaccine’s added value.
Merck Receives European Commission Approval For KEYTRUDA In Combination With Padcev For Adults With Resectable Muscle-Invasive Bladder Cancer
In brief
Merck’s KEYTRUDA‑Padcev combo gets EU approval, offering a new, chemotherapy‑free treatment for bladder cancer patients who cannot use cisplatin.
Merck Discontinues Bacterial Infection Drug in Europe
In brief
Merck is pulling Zinplava from the EU and U.S., ending a therapy that helped prevent recurrent Clostridium difficile infections.
European Commission Withdraws EU Marketing Authorisation For Zinplava At Merck Sharp & Dohme B.V.’s Request After Permanent Discontinuation For Commercial Reasons
In brief
Merck is discontinuing Zinplava, ending its EU presence after nine years of sales.
Palantir CTO Says Some AI Researchers Are So Sure It Will Cure Cancer They’ve Started 'Smoking' — Warns Both AI Extremes Reflect ‘Social Delusion’
In brief
Palantir’s CTO cautions that AI hype is often driven by belief rather than evidence, urging a safety‑first approach and challenging the influence of niche groups on AI policy.
A New War on Cancer? NIH's Vaccine Initiative Sparks Biotech Stock Rally
In brief
NIH’s cancer vaccine initiative is boosting biotech stocks as investors bet on faster, mRNA‑based cancer therapies.
Tempus AI Doubles Down On Moderna and Merck Cancer Vaccine Infrastructure
In brief
Tempus is deepening ties with Moderna and Merck on a personalized cancer vaccine, but the deal’s financial upside remains unclear, weighing on its stock price today.
Moderna, Vaxcyte and Novavax Are Trending After-Hours as Suspected Pneumonic Plague In Russia Stirs Anxiety
In brief
Vaccine stocks are reacting to a Russian plague scare and company‑specific moves, with Moderna and Vaxcyte seeing modest gains and Novavax sliding slightly.
Merck Says Investigational Skin Therapy Shows Potential
In brief
Merck’s Phase 2b tulisokibart trial for hidradenitis suppurativa hit its primary endpoint, but the market reacted mildly negatively.
Merck’s Tulisokibart Meets Phase 2b Primary Endpoint In Hidradenitis Suppurativa, Achieves HiSCR50 of 72% And 64% Vs 35% for Placebo At Week 16
In brief
Tulisokibart shows strong Phase 2b efficacy in HS, with 72 % HiSCR50 at high dose, outperforming placebo and supporting progression to later‑stage trials.
Merck, Daiichi Sankyo Scrap FDA Application for Lung Cancer Drug
In brief
Merck and Daiichi Sankyo pulled their accelerated‑approval application for I‑DXd after the FDA deemed the data inadequate, but Phase 3 studies will proceed.
Here’s How Much You Would Have Made Owning Merck & Co Stock In The Last 5 Years
In brief
Merck’s stock has outperformed the market, doubling a $100 investment over five years and delivering a 15.2% annualized return.
Merck, Daiichi Sankyo Voluntarily Withdraw Biologics License Application Approval In U.S. For Ifinatamab Deruxtecan To Treat Small Cell Lung Cancer After Discussions With FDA
In brief
Merck and Daiichi Sankyo pulled their accelerated‑approval filing for I‑DXd in ES‑SCLC after FDA feedback that the data were insufficient.
Merck Receives FDA Approval For Its Dual Oral Regimen Of WELIREG Plus LENMIVA For The Treatment Of Adult Patients With Advanced Renal Cell Carcinoma With A Clear Cell Component
In brief
Merck’s WELIREG plus LENVIMA combo gets FDA clearance after showing better PFS and ORR than cabozantinib in advanced ccRCC.
Alpha Buying: Follow the Money From NVIDIA and Merck
In brief
Big-name corporate investors are betting on the next wave of AI infrastructure and biotech innovation, but the real upside depends on how well the partnerships translate into commercial traction.
Merck Says Investigational Diabetes-Related Blindness Drug at Par With Roche’s Medicine
In brief
Merck’s remigromig shows visual‑acuity results on par with Lucentis but with higher safety concerns, giving Merck a foothold in the DME market while raising questions about tolerability.
Merck Says Topline Data From Phase 2b/3 BRUNELLO Trial Of Remigromig (MK-3000, Formerly EYE103) For Diabetic Macular Edema Met Its Primary Endpoint
In brief
Remigromig meets Phase 3 non‑inferiority in DME, opening a new therapeutic avenue for patients who do not fully respond to existing anti‑VEGF drugs.
Merck Says FDA Approves Update To US Product Label For WINREVAIR For Injection, 45mg, 60mg, Based On The Phase 3 HYPERION Trial
In brief
Merck’s FDA label approval for WINREVAIR in newly diagnosed PAH patients could broaden its use and improve patient outcomes.
Merck's Subcutaneous KEYTRUDA QLEX Approved In Japan For All Existing KEYTRUDA Indications
In brief
Merck’s new subcutaneous KEYTRUDA QLEX gets Japanese approval, enabling one‑minute injections for all current indications.
Merck Advances European Regulatory Approval For Keytruda Combination In Bladder Cancer
In brief
Merck’s Keytruda plus Padcev combo is poised for EU approval, broadening treatment options for bladder‑cancer patients and boosting Merck’s oncology portfolio.
EU CHMP Adopts Positive Opinion Recommending Approval Of KEYTRUDA, Merck’s Anti-PD-1 Therapy, In Combination With Padcev As Neoadjuvant Treatment For Adults With Resectable Muscle-Invasive Bladder Cancer
In brief
EU regulators are poised to approve the first PD‑1 inhibitor plus antibody‑drug conjugate combo for bladder cancer, based on strong Phase 3 data.
Moderna Stock More Than Doubled in a Month. Now Comes the Hard Part
In brief
Moderna’s Phase 3 melanoma win validates its mRNA cancer platform, but the real test lies in scaling manufacturing, securing approvals, and expanding to other cancers.
Novo Nordisk, Anthropic Team Up For AI Drug Research
In brief
Novo Nordisk’s new AI partnership with Anthropic could accelerate drug discovery and strengthen its competitive position in biopharma.
Company reports
Official filings (US SEC and linked cards)
No filings here yet
Official report cards for MRK will show up here when available.
Broad market indexes (like the S&P 500, a basket of 500 large US companies) are shown through popular funds that track them (for example SPY). Company profile and prices use live market data when available.